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1. INTRODUCTION {#jcmm13856-sec-0001}
===============

As the predominant liver malignancy, hepatocellular carcinoma (HCC) is the second major cause of cancer death in the world.[1](#jcmm13856-bib-0001){ref-type="ref"} In spite of remarkable efforts to discover novel therapeutic strategies against HCC, the long‐term survival rate remains dismal. Cancer metastasis and poor prognosis are two major obstacles in HCC therapy.[2](#jcmm13856-bib-0002){ref-type="ref"} Most of HCC patients still suffer from metastasis and recurrence after treatment. The molecular mechanism underlying HCC has not been clearly characterized. Thus, it is extremely critical to promote researches on molecular biomarkers which regulate metastatic behaviour and prognosis evaluation of HCC.[3](#jcmm13856-bib-0003){ref-type="ref"} Recently, an increasing number of studies have revealed the crucial role of non‐coding RNAs in HCC, including long non‐coding RNA (lncRNAs) and microRNAs (miRNAs).[4](#jcmm13856-bib-0004){ref-type="ref"}, [5](#jcmm13856-bib-0005){ref-type="ref"}

LncRNAs are a class of poor conserved endogenous RNAs longer than 200 nucleotides that do not encode proteins but regulate gene expression.[6](#jcmm13856-bib-0006){ref-type="ref"} In recent years, accumulating evidences have revealed the importance of lncRNAs on cancer metastasis and development, suggesting the involvement of lncRNAs in cancer progression.[7](#jcmm13856-bib-0007){ref-type="ref"}, [8](#jcmm13856-bib-0008){ref-type="ref"} The lncRNA Colorectal Neoplasia Differentially Expressed (CRNDE), which was initially found to increase in colorectal cancer, was also overexpressed in various malignant diseases including HCC.[9](#jcmm13856-bib-0009){ref-type="ref"} Current evidences have suggested that CRNDE exert influence on the propagation and metastasis of malignant carcinoma.[10](#jcmm13856-bib-0010){ref-type="ref"} However, the expression profiles and precise biological functions of CRNDE in HCC remain largely unknown.

On the other hand, miRNAs, a class of endogenous non‐coding RNAs with 20‐25 nucleotides length, have been proved to modulate mRNA stability and protein translation.[11](#jcmm13856-bib-0011){ref-type="ref"} MiRNAs play a crucial role in cancer development process such as differentiation, proliferation and metastasis.[12](#jcmm13856-bib-0012){ref-type="ref"} According to previous studies, microRNA 217 (miR‐217) was linked with cell progression as a tumour suppressor.[13](#jcmm13856-bib-0013){ref-type="ref"}, [14](#jcmm13856-bib-0014){ref-type="ref"} But, the mechanism of miR‐217 is still not clear in HCC.

Epithelial‐to‐mesenchymal transition (EMT), the process by which epithelial cells gain migratory and invasive properties, has been identified as an important process in cancer progression, especially in HCC.[15](#jcmm13856-bib-0015){ref-type="ref"} Dysregulated expression of lncRNAs and miRNAs were reported to mediate the EMT progression in HCC cells.[16](#jcmm13856-bib-0016){ref-type="ref"}, [17](#jcmm13856-bib-0017){ref-type="ref"} Consequently, lncRNAs and miRNAs are considered as potential novel therapeutic targets against the poor prognosis and metastasis of HCC. Meanwhile, mitogen‐activated protein kinase 1 (*MAPK1*) is involved in a variety of cancer cell processes such as proliferation and migration.[18](#jcmm13856-bib-0018){ref-type="ref"} *MAPK1* has been proved to mediate EMT as an intracellular signalling molecule, and some signalling molecules can also affect EMT progression through MAPK1 pathway.[19](#jcmm13856-bib-0019){ref-type="ref"} Zhang et al found that miR‐217 regulated tumour growth and apoptosis by targeting the MAPK signalling pathway in colorectal cancer.[20](#jcmm13856-bib-0020){ref-type="ref"} Nevertheless, there are only a few reports about the interaction among CRNDE, miR‐217 and *MAPK1* in HCC cells.

Recently, some studies revealed that one potential function of lncRNAs was to directly interact with miRNAs, regulating their expression and activity.[21](#jcmm13856-bib-0021){ref-type="ref"} In recently described mechanism, lncRNAs might function as competitive endogenous RNAs to sponge specific miRNAs, thereby mediating the de‐repression of miRNAs targets.[22](#jcmm13856-bib-0022){ref-type="ref"} For instance, lncRNA MALAT1 facilitated migration and invasiveness by modulating miR‐1 in breast cancer.[23](#jcmm13856-bib-0023){ref-type="ref"} LncRNA H19 regulated cancer cell propagation by regulating miR‐194‐5p.[24](#jcmm13856-bib-0024){ref-type="ref"} LncRNA UCA1 exerted oncogenic effects by targeting mir‐193a‐3p in lung cancer.[25](#jcmm13856-bib-0025){ref-type="ref"} We therefore hypothesized that CRNDE might also directly interact with some particular miRNAs.

Herein, we reported that CRNDE and miR‐217 had different expression in HCC. Our results elucidated that CRNDE could modulate MAPK1 pathway by competitively inhibiting miR‐217, thereby promoting HCC cells migration and invasiveness. Our findings exhibited that CRNDE might serve as a potential therapeutic target against HCC.

2. MATERIALS AND METHODS {#jcmm13856-sec-0002}
========================

2.1. Patients and samples {#jcmm13856-sec-0003}
-------------------------

HCC tissues were obtained from 46 patients with informed consents of Tongji Hospital. None of these patients received chemotherapeutic treatment or radical surgical treatment. All adjacent tissues and tumour tissues were preserved in liquid nitrogen under −80°C. This study was approved by the Institutional Ethics Committee of Tongji Hospital.

2.2. Microarray {#jcmm13856-sec-0004}
---------------

Ten fresh human HCC tissues and paired para‐tumour tissues were acquired. Total RNA was extracted from these tissues and pooled. The collected RNA samples serve as templates for cDNA synthesis. Probe labelling and hybridization were carried out by Affymetrix GeneChip Human genome U133 plus 2.0 Array and the arrays were scanned by Affymetrix GeneChip Scanner 3000 7G (Affymetrix, California, USA). Then, we employed whole genome microarray expression profiling as a discovery platform to identify differentially expressed genes (DEGs) between HCC and normal control. After the preprocessing of the raw expression data, the DEGs were analysed using limma package in R/Bioconductor. The criteria for DEGs were based on fold change\>2 combined with adjusted *P* value less than 0.05.

2.3. Cell lines and cultures {#jcmm13856-sec-0005}
----------------------------

The HCC cell lines including HepG2, Huh‐7, HCCLM3, SNU449, SNU475, HepaRG and human normal hepatic cell line HL‐7702 were gained from BeNa Culture Collection (Beijing, China). HepG2, Huh‐7 and HCCLM3 cell lines were maintained in high‐glucose DMEM medium (Invitrogen, Carlsbad, CA, USA) with 10% foetal bovine serum (FBS, Invitrogen, CA, USA). HL‐7702, SNU449, SNU475 and HepaRG cells were cultured in RPMI‐1640 medium (GIBCO, Carlsbad, CA, USA) with 10% FBS (Invitrogen).

2.4. Cell transfection {#jcmm13856-sec-0006}
----------------------

PcDNA3.1‐CRNDE, sh‐CRNDE, pcDNA3.1‐MAPK1, sh‐MAPK1, miR‐217 mimics, anti‐miR‐217 and negative control were provided by GenePharma (Shanghai, China). Transfection of HepG2 and Huh‐7 cells was conducted using Lipofectamine^™^ 2000 (Invitrogen, Carlsbad, CA, USA). Transfected cells were cultured in 6‐well plates. After 48‐h cultivation, the cells were collected for subsequent analyses.

2.5. QRT‐PCR assay {#jcmm13856-sec-0007}
------------------

Isolation of total RNA was conducted by TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Quantitative reverse transcription PCR (qRT‐PCR) was performed using the THUNDERBIRD SYBR^®^ qPCR Mix (Toyobo, Japan). All reactions were run as follows: 94°C, 120 second; 94°C, 30 second; 56°C, 30 second; 72°C, 60 second; 30 cycles. Primer sequences were exhibited at Table [1](#jcmm13856-tbl-0001){ref-type="table"}.

###### 

QRT‐PCR primer sequence

  Name             Primer sequence (5′‐3′)
  ---------------- -------------------------
  CRNDE            
  Forward primer   ATATTCAGCCGTTGGTCTTTGA
  Reverse primer   TCTGCGTGACAACTGAGGATTT
  miR‐217          
  Forward primer   TTGAGGTTGCTTCAGTGA
  Reverse primer   GGAGTAGATGATGGTTAGC
  MAPK1            
  Forward primer   GGTGCCTCCTCTTGACTTCC
  Reverse primer   AACCTGAACCTGACTGTCCATT
  GADPH            
  Forward primer   AACGGATTTGGTCGTATTG
  Reverse primer   GGAAGATGGTGATGGGATT
  U6               
  Forward primer   CTCGCTTCGGCAGCACA
  Reverse primer   AACGCTTCACGAATTTGCGT
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2.6. Dual luciferase reporter assay {#jcmm13856-sec-0008}
-----------------------------------

The wild‐type CRNDE and *MAPK1* 3′UTR sequence were amplified, and then, CRNDE‐mut, *MAPK1*‐mut, CRNDE‐wt and *MAPK1*‐wt were inserted into pmirGLO luciferase carrier (Promega, Madison, WI, USA). After that, pmirGLO‐CRNDE‐mut, pmirGLO‐CRNDE‐wt, mirGLO‐*MAPK1*‐mut, pmirGLO‐*MAPK1*‐wt or pmirGLO‐NC was transfected, respectively, into HepG2 or Huh‐7 cells with Lipofectamine^™^ 2000 (Invitrogen, Carlsbad, CA, USA). 100 nmol L^−1^ miR‐217 mimics and miR‐NC (GenePharma, Shanghai, China) were transfected subsequently into HepG2 or Huh‐7 cells. Luciferase activity was examined under the guidelines of the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA).

2.7. MTT assay {#jcmm13856-sec-0009}
--------------

The cellular proliferation viability of HepG2 and Huh‐7 cells was determined by MTT (3‐(4, 5‐Dimethylthiazol2‐yl)‐2, 5‐Diphenyl Tetrazolium Bromide) assay. The HCC cells were planted in 96‐well plates and rendered quiescent by incubation in the serum‐free medium for 24 hour. Then, the old culture medium was removed and the fresh medium containing 5 mg/mL MTT (Sigma‐Aldrich, St. Louis, MO, USA) was added at 37°C. The MTT colorimetric assay was performed to detect cell proliferation after 1, 2, 3, 4, 5 day of incubation. The absorbance of resulting formazan crystals (solubilized with DMSO) was read at 490 nm on ELISA plate reader.

2.8. BrdU staining assay {#jcmm13856-sec-0010}
------------------------

Transfected cells were seeded on coverslips in 96‐well plates and cultured overnight. BrdU (10 μg/mL) was added to the culture medium and cells further incubated for 1 hour. Cells were immediately fixed in 4% paraformaldehyde for 10 minute and stained with an anti‐BrdU antibody (Biocompare, South San Francisco, CA) per manufacturer\'s instructions. The coverslips were counterstained with DAPI and imaged acquired with fluorescence microscopy (Olympus, Tokyo, Japan). Results were expressed as the cell number per field.

2.9. Transwell assay {#jcmm13856-sec-0011}
--------------------

HepG2 and Huh‐7 cells were suspended with fresh medium containing 1% FBS. For observing cell migration, cells were deposited in Transwell upper chambers (Corning Inc., Corning, NY, USA) and DMEM medium was added to lower chamber. For observing cell invasion, cells were seeded to the upper chamber coated with 50 matrigel gel (BD Bioscience, San Jose, CA, USA) and the bottom chamber was added with DMEM medium and 10% FBS. After fixed and stained for 30 minutes, cells were observed under a microscope.

2.10. Wound healing assay {#jcmm13856-sec-0012}
-------------------------

Wound healing assay was performed for analysis of cell migration in vitro. Briefly, HepG2 and Huh‐7 cells were transfected with CRNDE, sh‐CRNDE, CRNDE+miR‐217 mimics, sh‐CRNDE+anti‐miR‐217, anti‐miR‐217, miR‐217 mimics, anti‐miR‐217+sh‐MAPK1, miR‐217 mimics+*MAPK1* and negative control. The HepG2 and Huh‐7 cells were cultured in 6‐well plates (5 × 10^5^/well) and incubated overnight. Culture inserts were removed after appropriate cell attachment and washed twice using PBS. Afterwards, cells were added in the DMEM medium with 10% FBS. At 0 and 24 hour after scratch would formation, images were obtained using an inverted microscope (Nikon, Tokyo, Japan) at a magnification of 40 × and were measured by Image Pro Plus software (Media Cybernetics, Inc., Rockville, MD, USA).

2.11. Western blot {#jcmm13856-sec-0013}
------------------

After washed with PBS, cells were lysed with RIPA lysate (Beyotime, Shanghai, China). Protein concentrations were determined using Pierce BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Protein was resolved by sodium dodecyl sulphate‐polyacrylamide gel electrophoresis (SDS‐PAGE) and electrophoretically transferred to polyvinylidene fluoride (PVDF) membrane (Invitrogen, USA). Afterwards, membranes were incubated with primary antibodies (Anti‐E‐Cadherin, ab1416, 1:50; Anti‐Mucin‐1, ab109185, 1:1000; Anti‐Vimentin, ab8978, 1/100; Anti‐Fibronectin, ab23750, 1 μg/mL; Anti‐c‐Myc, ab39688, 1/500; Anti‐β‐Actin, ab11003, 1/500, Abcam, Cambridge, MA, USA; Anti‐MAPK1, 1:100, Bosterbio, USA). Subsequently, we added IgG‐HRP labelled goat anti‐mouse secondary antibody (ab205719, 1:10000, Abcam, Cambridge, MA, USA). The immunoreactive proteins were visualized using the ECL Detection System (Life technologies, Gaithersburg, MD, USA).

2.12. Statistical analysis {#jcmm13856-sec-0014}
--------------------------

Mean ± standard deviation (SD) presented all quantitative values. Student\'s *t* test was utilized for comparison between two groups. Paired *t* test was used for CRNDE/miR‐147 comparison between adjacent and tumour tissues, unpaired *t* test was applied for other comparison between two groups. One‐way analysis of variance (ANOVA) was applied for comparison in multi‐groups. Statistical analyses were conducted by GraphPad Prism v6.0 (Graphpad Software, La Jolla, CA, USA). The difference was statistically significant when *P* \< 0.05.

3. RESULTS {#jcmm13856-sec-0015}
==========

3.1. CRNDE was screened out by microarray analysis {#jcmm13856-sec-0016}
--------------------------------------------------

Ten pairs of HCC tissues and adjacent tissues were used to perform microarray. Fold change \> 2 and *P* \< 0.05 were applied to explore the abnormal lncRNA expressions. The volcanic plot and the heat map of lncRNA expression reflected that compared with adjacent normal tissues, CRNDE was up‐regulated in HCC tumour tissues. (Figure [1](#jcmm13856-fig-0001){ref-type="fig"}A and B).

![CRNDE was screened out by bioinformatics analysis. (A) The volcanic plot showed that CRNDE was significantly overexpressed in hepatocellular carcinoma (*P* \< 0.001). (B) The heat map showed the significantly highly or lowly expression genes in HCC tissues, and CRNDE was sharply up‐regulated in HCC tissues](JCMM-22-5862-g001){#jcmm13856-fig-0001}

3.2. CRNDE highly expressed while miR‐217 had a low expression in HCC cells and there was a targeted regulatory relationship between them {#jcmm13856-sec-0017}
-----------------------------------------------------------------------------------------------------------------------------------------

The overexpression of CRNDE was further confirmed by qRT‐PCR in 46 HCC specimens (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}A, *P* \< 0.05). The CRNDE was also highly expressed in various liver cancer cell lines compared with the one in normal hepatocyte HL‐7702. Among HCC cell lines, CRNDE was relatively more highly expressed in Huh‐7 cells and more lowly expressed in HepG2 cells (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}A, *P* \< 0.01). Huh‐7 and HepG2 cell lines were used in follow‐up assays. The correlation between CRNDE and clinicopathologic characteristic of patients is shown in Table [2](#jcmm13856-tbl-0002){ref-type="table"}. Chi‐square test demonstrated that CRNDE had a close relation with AJCC stage and cancer progression like migration and invasion. Among these 46 HCC samples, miR‐217 was detected down‐regulated in tumour tissues (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}B, *P* \< 0.01). The miR‐217 was also lowly expressed in various liver cancer cell lines compared with the one in normal hepatocyte HL‐7702 (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}B, *P* \< 0.05, *P* \< 0.01). Pearson\'s correlative analysis suggested miR‐217 expression was negatively correlated with CRNDE expression (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}C, *P* \< 0.001). The transfection efficiency test was applied for further experiments. QRT‐PCR results showed that CRNDE was significantly changed after the transfection of CRNDE or sh‐CRNDE while miR‐217 expression level was conspicuously fluctuated after the transfection of anti‐miR‐217 or miR‐217 mimics (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}D, *P* \< 0.01). Bioinformatics and dual luciferase reporter assay demonstrated that miR‐217 was the target of CRNDE (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}E and F, *P* \< 0.01). The up‐regulated CRNDE decreased miR‐217 expression in HepG2 cells, while the inhibited CRNDE dramatically increased miR‐217 expression in Huh‐7 cells (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}G, *P* \< 0.01). However, different miR‐217 expression levels scarcely influenced CRNDE expression level (Figure [2](#jcmm13856-fig-0002){ref-type="fig"}H). Based on above results, we hypothesized that the development of hepatocellular carcinoma might be closely related to the overexpression of CRNDE and low expression of miR‐217. Based on targeted regulatory relationship between CRNDE and miR‐217 was confirmed, we speculated CRNDE might affect HCC process via regulating miR‐217.

![Circumstance of CRNDE/miR‐217 expression in vitro/*vivo* and the relationship between them. (A) CRNDE expression in tissues and HCC cells. (B) MiR‐217 expression in tissues and HCC cells. (C) Pearson\'s correlation analysis revealed CRNDE expression was negatively related with miR‐217 expression in HCC tissues. (D) Transfection efficiencies test of CRNDE/sh‐CRNDE and miR‐217/anti‐miR‐217 verified by qRT‐PCR. (E) The sequence of binding sites between CRNDE and miR‐217, and the sequence of mutant CRNDE. (F) Dual luciferase reporter assays showed that miR‐217 could regulate the luciferase activity of CRNDE‐WT, rather than CRNDE‐Mut. (G) QRT‐PCR showed that CRNDE could negatively regulate miR‐217 expression in HCC cells. CRNDE could significantly decrease the expression of miR‐217 in HepG2 cells while sh‐CRNDE could significantly increase the expression of miR‐217 in Huh‐7 cells. (H) MiR‐217 could not inversely regulate CRNDE expression in HCC cells. \**P* \< 0.05, \*\**P* \< 0.01, compared with adjacent/HL‐7702/NC group](JCMM-22-5862-g002){#jcmm13856-fig-0002}

###### 

Correlation between CRNDE expression and clinicopathologic characteristics in 46 cases of HCC tissues

  Characteristics total cases   N of cases 46   CRNDE expression   *P* value[a](#jcmm13856-note-0003){ref-type="fn"}   
  ----------------------------- --------------- ------------------ --------------------------------------------------- ---------------------------------------------------
  Age (years)                                                                                                          
  ≤60                           30              15                 15                                                  0.7628
  \>60                          16              9                  7                                                   
  Gender                                                                                                               
  Male                          27              16                 11                                                  0.3695
  Female                        19              8                  11                                                  
  AJCC stage                                                                                                           
  I                             14              10                 4                                                   0.0104[\*](#jcmm13856-note-0002){ref-type="fn"}
  II                            21              13                 8                                                   
  III                           7               1                  6                                                   
  IV                            4               0                  4                                                   
  Tumour size                                                                                                          
  ≤3 cm                         37              22                 15                                                  0.0660
  \>3 cm                        9               2                  7                                                   
  Vascular invasion                                                                                                    
  Yes                           15              3                  12                                                  0.0122[\*](#jcmm13856-note-0002){ref-type="fn"}
  No                            31              19                 12                                                  
  Distant metastasis                                                                                                   
  M~0~                          27              18                 9                                                   0.0031[\*\*](#jcmm13856-note-0002){ref-type="fn"}
  M~1~                          19              4                  15                                                  

\**P* \< 0.05, \*\**P* \< 0.01; AJCC, American Joint Committee on Cancer.

Chi‐square test.
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3.3. CRNDE could enhance proliferation, migration and invasion through the promotion of EMT process via regulating miR‐217 in HCC cells {#jcmm13856-sec-0018}
---------------------------------------------------------------------------------------------------------------------------------------

MTT assay was applied to detect the proliferation level while BrdU staining assay was utilized for further verification of cell propagation ability. MTT assay showed that cell proliferation level was increased by CRNDE and the condition was offset with the addition of miR‐217 mimics. In sh‐CRNDE group, cell proliferation was significantly restrained and the viability of proliferation was recovered with the addition of anti‐miR‐217 (Figure [3](#jcmm13856-fig-0003){ref-type="fig"}A, *P* \< 0.01). BrdU staining assay showed that cell number per unit area was increased after the transfection of CRNDE and the cell quantity was restored by miR‐217 mimics. In Huh‐7 cells, sh‐CRNDE could significantly decrease the cell number and this condition could be eliminated by anti‐miR‐217 (Figure [3](#jcmm13856-fig-0003){ref-type="fig"}B, *P* \< 0.01).

![CRNDE/miR‐217 played a role in regulating HCC cell proliferation. (A) MTT assay showed CRNDE and down‐regulated miR‐217 could accelerate cell proliferation while down‐regulated CRNDE and miR‐217 could slow down cell proliferation. (B) BrdU staining assay showed the cell propagation condition in different transfection groups. \*\**P* \< 0.01, compared with NC group. ^\#\#^ *P* \< 0.01, compared with CRNDE+miR‐217/sh‐CRNDE+ anti‐miR‐217 group](JCMM-22-5862-g003){#jcmm13856-fig-0003}

Transwell assay and wound healing assay were applied to detect the migration and invasion levels while Western blot was utilized to verify the EMT process of HCC cells. The up‐regulation of CRNDE significantly promoted migration and invasive abilities of HepG2 cells. With the addition of miR‐217 mimics, the metastatic capabilities were significantly weakened (Figure [4](#jcmm13856-fig-0004){ref-type="fig"}A, *P* \< 0.01). In Huh‐7 cells, sh‐CRNDE conspicuously decreased cell migration and invasion levels. After the transfection of anti‐miR‐217, this condition was revered (Figure [4](#jcmm13856-fig-0004){ref-type="fig"}A, *P* \< 0.01). Wound healing assay further proved CRNDE could accelerate cell migration and miR‐217 would block cell metastasis (Figure [4](#jcmm13856-fig-0004){ref-type="fig"}B, *P* \< 0.01). Generally, loss of E‐cadherin/Mucin‐1 and activation of Vimentin/Fibronectin expression are considered to be the fundamental events in EMT. As shown in Figure [4](#jcmm13856-fig-0004){ref-type="fig"}C, overexpressed CRNDE observably decreased E‐cadherin/Mucin‐1 protein levels and increased Vimentin/Fibronectin protein levels (*P* \< 0.01), whereas the miR‐217 affected on the contrary (*P* \< 0.01). Sh‐CRNDE conspicuously increased E‐cadherin/Mucin‐1 protein levels and decreased Vimentin/Fibronectin protein levels (*P* \< 0.01), whereas the anti‐miR‐217 had an opposite effect (*P* \< 0.01). Therefore, CRNDE enhance proliferation, migration and invasion by promoting EMT process via regulating miR‐217 in HCC cells was evidenced preliminarily.

![CRNDE/miR‐217 took part in cell migration, invasion and EMT regulatory process. (A) Transwell assay showed that CRNDE and down‐regulated miR‐217 could enhance cell migration and invasion abilities, down‐regulated CRNDE and miR‐217 could weaken capacities of cell migration and invasion. (B) Wound healing assay was performed for further verification of cell migration abilities. (C) Western blot exhibited the protein expression levels of epithelial makers E‐cadherin/Mucin‐1 were reduced by CRNDE and anti‐miR‐217. Besides, the results were conversed by miR‐217 and sh‐CRNDE. Furthermore, the protein expression levels of mesenchymal markers Vimentin/Fibronectin were increased following the EMT activation. \*\**P* \< 0.01, compared with NC group. ^\#\#^ *P* \< 0.01, compared with CRNDE+miR‐217/sh‐CRNDE+ anti‐miR‐217 group](JCMM-22-5862-g004){#jcmm13856-fig-0004}

3.4. *MAPK1* was the target of miR‐217 and was regulated by CRNDE/miR‐217 axis {#jcmm13856-sec-0019}
------------------------------------------------------------------------------

Bioinformatics analysis was utilized to predict that *MAPK1* was the possible targeting genes of miR‐217 (Figure [5](#jcmm13856-fig-0005){ref-type="fig"}A). Dual luciferase reporter assay demonstrated that miR‐217 mimics could regulate the luciferase activity of *MAPK1*‐wt, but had no obvious effect on *MAPK1*‐mut (Figure [5](#jcmm13856-fig-0005){ref-type="fig"}B, *P* \< 0.01). HepG2 transfected with miR‐217 inhibitors and Huh‐7 transfected with miR‐217 mimics were used to test the influence of miR‐217 on *MAPK1*. The qRT‐PCR and Western blot results suggested that miR‐217 negatively regulated *MAPK1* expression, *MAPK1* was regulated by miR‐217 (Figure [5](#jcmm13856-fig-0005){ref-type="fig"}C and D, both *P* \< 0.01). In order to further investigate the role of miR‐217 and *MAPK1*, HepG2 cells were transfected with extra CRNDE, raising *MAPK1* expression. More importantly, CRNDE+miR‐217 mimics group reversed the up‐regulation of *MAPK1* (Figure [5](#jcmm13856-fig-0005){ref-type="fig"}E and F, both *P* \< 0.01). Conversely, sh‐CRNDE+anti‐miR‐217 group reversed the down‐regulation of *MAPK1* reduced by sh‐CRNDE group in Huh‐7 cells (Figure [5](#jcmm13856-fig-0005){ref-type="fig"}E and F, both *P* \< 0.01). Transfection efficiency test showed *MPAK1* expression level was significantly changed after the transfection of *MAPK1* or sh‐MAPK1 (Figure [5](#jcmm13856-fig-0005){ref-type="fig"}G, *P* \< 0.01). To investigate whether *MAPK1* can reversely regulate up‐stream CRNDE/miR‐217 expression, the qRT‐PCR was applied. The qRT‐PCR results of CRNDE/miR‐217 demonstrated that different *MAPK1* expression levels scarcely influenced up‐stream CRNDE/miR‐217 expression level (Figure [5](#jcmm13856-fig-0005){ref-type="fig"}H).

![*MAPK1* was a target of miR‐217 and positively regulated by CRNDE in HCC cells. (A) The sequence of binding sites between *MAPK1* and miR‐217, and the sequence of mutant *MAPK1*. (B) Dual luciferase reporter assays showed miR‐217 regulated the luciferase activity of *MAPK1*‐wt, rather than *MAPK1*‐mut in HCC cells. (C, D) Quantitative real‐time PCR and Western blot analysis revealed that miR‐217 inhibitors could significantly increase the expression of *MAPK1* in HepG2 cells. MiR‐217 mimics could significantly decrease the expression of *MAPK1* in Huh‐7 cells. (E, F) MiR‐217 restoration reduced the high expression of *MAPK1* in CRNDE‐overexpressing HepG2 cells. MiR‐217 knockdown increased the low expression of *MAPK1* in CRNDE‐knockout Huh‐7 cells. (G) Transfection efficiencies test verified by qRT‐PCR. (H) *MAPK1* could not inversely regulate up‐stream CRNDE/miR‐217 expression in HCC cells. \*\**P* \< 0.01, compared with NC group. ^\#\#^ *P* \< 0.01, compared with CRNDE+miR‐217/sh‐CRNDE+anti‐miR‐217 group](JCMM-22-5862-g005){#jcmm13856-fig-0005}

3.5. MiR‐217/*MAPK1* regulatory axis affected HCC cell proliferation, migration, invasion enhance proliferation, migration and invasion through EMT process {#jcmm13856-sec-0020}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

MTT assay showed that HepG2 cell proliferation level was increased in anti‐miR‐217 group and the condition was offset with the addition of sh‐MAPK1. In Huh‐7 cells, cell proliferation was significantly restrained by miR‐217 mimics and the viability of proliferation was recovered with the addition of *MAPK1* (Figure [6](#jcmm13856-fig-0006){ref-type="fig"}A, *P* \< 0.01). BrdU staining assay showed that cell number per unit area was increased after the transfection of anti‐miR‐217 and the cell quantity was restored by sh‐MAPK1. In Huh‐7 cells, miR‐217 could significantly decrease the cell number and this condition could be eliminated by *MAPK1* (Figure [6](#jcmm13856-fig-0006){ref-type="fig"}B, *P* \< 0.01).

![*MAPK1* played a role in HCC cell proliferation through miR‐217 regulation. (A) MTT assay showed that sh‐MAPK1 could largely reverse the accelerating effects of anti‐miR‐217 on proliferation of HepG2 cells while *MAPK1* abrogated the suppressive effects of miR‐217 mimics on proliferation of Huh‐7 cells. (B) BrdU staining assay demonstrated HCC cell proliferation ability was enhanced by anti‐miR‐217 or *MAPK1* while it was weakened by sh‐MAPK1 or miR‐217. \*\**P* \< 0.01, compared with NC group. ^\#\#^ *P* \< 0.01, compared with anti‐miR‐217+ sh‐MAPK1/miR‐217+*MAPK1* group](JCMM-22-5862-g006){#jcmm13856-fig-0006}

Transwell assay and wound healing assay showed that down‐regulation of miR‐217 significantly promoted migration and invasive abilities of HepG2 cells. With the addition of sh‐MAPK1, the metastatic capabilities were significantly weakened (Figure [7](#jcmm13856-fig-0007){ref-type="fig"}A and B, *P* \< 0.01). In Huh‐7 cells, miR‐217 conspicuously decreased cell migration and invasion levels. After the transfection of *MAPK1*, this condition was revered (Figure [7](#jcmm13856-fig-0007){ref-type="fig"}A and B, *P* \< 0.01). Besides, down‐regulated miR‐217 observably decreased E‐cadherin/Mucin‐1 protein levels and increased Vimentin/Fibronectin protein levels, whereas sh‐MAPK1 affected on the contrary (Figure [7](#jcmm13856-fig-0007){ref-type="fig"}C, *P* \< 0.01). MiR‐217 conspicuously increased E‐cadherin/Mucin‐1 protein levels and decreased Vimentin/Fibronectin protein levels, whereas the *MAPK1* generated an opposite effect (Figure [7](#jcmm13856-fig-0007){ref-type="fig"}C, *P* \< 0.01). To sum up, miR‐217/*MAPK1* regulatory axis played a role in regulating HCC progress.

![MiR‐217/*MAPK1* regulated cell migration, invasion and EMT regulatory process in HCC cells. (A) Transwell assays showed that sh‐MAPK1 could largely reverse the promoting effects of anti‐miR‐217 on migration and invasion of HepG2 cells. *MAPK1* could abrogate the suppressive effects of miR‐217 mimics on migration and invasion of Huh‐7 cells. (B) Wound healing assay was performed for further verification of cell migration abilities. (C) Sh‐MAPK1 could largely reverse the promoting effects of anti‐miR‐217 on EMT progression of HepG2 cells while *MAPK1* could abrogate the suppressive effects of miR‐217 mimics on EMT progression of Huh‐7 cells. \*\**P* \< 0.01, compared with NC group. ^\#\#^ *P* \< 0.01, compared with anti‐miR‐217+sh‐MAPK1/miR‐217+*MAPK1* group](JCMM-22-5862-g007){#jcmm13856-fig-0007}

3.6. CRNDE/miR‐217 were related with the expression of EMT markers and participated in mediating MAPK1 signalling {#jcmm13856-sec-0021}
-----------------------------------------------------------------------------------------------------------------

Pearson correlative analysis suggested the expression of EMT marker E‐cadherin was negatively correlated with CRNDE expression but positively correlated with miR‐217 expression. Vimentin, the mesenchymal marker of EMT, was positively correlated with CRNDE expression while negatively related to miR‐217 (Figure [8](#jcmm13856-fig-0008){ref-type="fig"}A). The results demonstrated that CRNDE/miR‐217 had a close relation with EMT process. As for MAPK1 signalling, the protein levels of *MAPK1* and its down‐stream *c‐Myc* were detected by Western blot with the different treatments. CRNDE or down‐regulated miR‐217 could significantly enhance *MAPK1*/*c‐Myc* protein expression and the potentiation could be eliminated by miR‐217 or sh‐MAPK1 (Figure [8](#jcmm13856-fig-0008){ref-type="fig"}B, *P* \< 0.01). Down‐regulated CRNDE and miR‐217 conspicuously reduced *MAPK1*/*c‐Myc* protein expression, and the inhibiting effect was removed by anti‐miR‐217 or *MAPK1* (Figure [8](#jcmm13856-fig-0008){ref-type="fig"}C, *P* \< 0.01). Combined the results, it was proved that MAPK1 signalling was mediated by CRNDE/miR‐217 regulatory axis.

![CRNDE/miR‐217 were related to EMT process and MAPK1 signalling pathway. (A) Expression of EMT markers was related with CRNDE/miR‐217 expression. (B, C) The protein expression levels of *MAPK1* and down‐stream *c‐Myc* were regulated by CRNDE/miR‐217 axis. \*\**P* \< 0.01, compared with NC group. ^\#\#^ *P* \< 0.01, compared with anti‐miR‐217+sh‐MAPK1/miR‐217+*MAPK1* group](JCMM-22-5862-g008){#jcmm13856-fig-0008}

4. DISCUSSION {#jcmm13856-sec-0022}
=============

HCC has been regarded as a common malignant tumour for high recurrence and poor prognosis.[2](#jcmm13856-bib-0002){ref-type="ref"} Targeting the metastasis of HCC cells has become a therapeutic object for developing novel HCC treatments. So far, mounting evidences have indicated that lncRNAs had close connection with the HCC progression.[26](#jcmm13856-bib-0026){ref-type="ref"} For instance, Lan et al have reported that HCC tumorigenesis was accelerated by lncRNA PVT1.[27](#jcmm13856-bib-0027){ref-type="ref"} In addition, Lu et al proved that overexpressed lncRNA HOXD‐AS1 was a critical regulator of metastasis in HCC.[28](#jcmm13856-bib-0028){ref-type="ref"} CRNDE has been identified to promote tumour development,[9](#jcmm13856-bib-0009){ref-type="ref"}, [29](#jcmm13856-bib-0029){ref-type="ref"} and its function in HCC remains had been preliminarily revealed in some research, such as Chen et al revealed that CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR‐384.[30](#jcmm13856-bib-0030){ref-type="ref"} In this study, CRNDE expression was proved to be remarkably increased in HCC and the results are consistent with previous studies. Up till now, a number of lncRNAs have been characterized as regulators in HCC cells metastasis process.[31](#jcmm13856-bib-0031){ref-type="ref"} In in vitro experiments, we found that CRNDE facilitated HCC cells metastasis and promoted the EMT progression by decreasing E‐cadherin/Mucin‐1 and increasing Vimentin/Fibronectin. Thus, we concluded that CRNDE functioned as a tumour promoter by accelerating metastasis and EMT progression of HCC cells.

Increasing studies have reported that abnormally expressed lncRNAs can function as competitive endogenous RNA (ceRNA) to modulate miRNAs and play key roles in the occurrence and development of malignant tumour.[32](#jcmm13856-bib-0032){ref-type="ref"}, [33](#jcmm13856-bib-0033){ref-type="ref"} In our study, bioinformatics analysis and luciferase reporter assay verified that miR‐217 was a target of CRNDE in HCC cells. By modulating expression levels of CRNDE and miR‐217, we found that CRNDE negatively mediated miR‐217 expression, while the dysregulated miR‐217 did not influence CRNDE expression reversely. According to the ceRNA theory, we supposed that CRNDE could act as a sponge to negatively regulate miR‐217, exerting its promoting effects on HCC cells via modulating miR‐217. Previous study Yu et al discovered that CRNDE involves in the cell proliferation, migration and invasion of colorectal cancer cells via increasing the expression of *TCF7L2* and activity of Wnt/β‐catenin signalling through binding miR‐217 competitively[34](#jcmm13856-bib-0034){ref-type="ref"} and the consequence was consisted with our experimental results.

To further investigate the molecular network of miR‐217, we investigated *MAPK1*, a downstream target of miR‐217. Previous studies have confirmed that increased *MAPK1* expression could function as tumour promoter in HCC.[35](#jcmm13856-bib-0035){ref-type="ref"}, [36](#jcmm13856-bib-0036){ref-type="ref"} Tang et al demonstrated that *MAPK1* was capable to regulate cell propagation and metastasis in ovarian cancer.[37](#jcmm13856-bib-0037){ref-type="ref"} Li et al reported the effect of *MAPK1* gene on metastasis and EMT progression in cervical cancer.[19](#jcmm13856-bib-0019){ref-type="ref"} Consistently, our results showed that *MAPK1* down‐regulated by miR‐217 facilitated metastasis and EMT process of HCC cells, indicating that miR‐217 suppressed HCC via negatively modulating *MAPK1* expression.

Generally speaking, lncRNAs can act as miRNAs sponges to reduce their regulatory effect on specific mRNAs. Zhu et al reported that lncRNA H19 sponged miR‐675 and repressed prostate cancer metastasis by targeting TGFB1.[38](#jcmm13856-bib-0038){ref-type="ref"} Huan et al revealed that lncRNA CRNDE activated Wnt/β‐catenin pathway through acting as sponge of miR‐136 in breast cancer.[39](#jcmm13856-bib-0039){ref-type="ref"} We did experiments to further explore the underlying mechanisms involved in CRNDE, miR‐217 and *MAPK1*, and we found that CRNDE could positively regulate the expression of *MAPK1*, but this increase was reversed by miR‐217 restoration. Moreover, the knockdown or restoration of miR‐217 also altered the positive effects of CRNDE on metastasis and EMT progression in HCC cells. Therefore, based on our results and existed literatures, we concluded that CRNDE participated in the regulation of *MAPK1* through interacting with miR‐217, which exert influence on HCC process.

As for MAPK1 signalling pathway, we detected *MAPK1* and down‐stream *c‐Myc* protein expression levels by Western blot. The results showed that CRNDE could promote MAPK1 signalling while miR‐217 worked on the contrary. There was a lot of evidences had proved that MAPK1 signalling and its down‐stream pathway played a role in regulating proliferation, migration, invasion and EMT. Hermeking et al identified that the cyclin‐dependent kinase 4 (*CDK4*) gene as a transcriptional target of *c‐Myc*. The prototypic oncogene *c‐Myc* encodes a transcription factor that can drive proliferation by promoting downstream cell cycle pathway.[40](#jcmm13856-bib-0040){ref-type="ref"} Furthermore, Shi et al proved c‐Myc was the major transcription factor promoting *VEGF* expression,[41](#jcmm13856-bib-0041){ref-type="ref"} Fantozzi et al discovered VEGF signalling‐mediated angiogenesis links EMT‐induced cancer stemness to tumour initiation.[42](#jcmm13856-bib-0042){ref-type="ref"} *VEGF* promoted tension‐independent FAK signalling activation which played an important role in cell migration and invasion.[43](#jcmm13856-bib-0043){ref-type="ref"} Above all, MAPK1 signalling was connected to downstream cell cycle, VEGF and FAK signalling which was known by regulating proliferation, metastasis and EMT process. Combined with the result of our study, it was proved that CRNDE/miR‐217 mediated HCC progress via MAPK1 signalling pathway. However, to well elucidate the pathogenesis of HCC, some deficiencies in our study should be ameliorated in future researches. For example, in vivo experiment should be employed to verify the molecular mechanism of CRNDE/miR‐217/*MAPK1* axis.

In conclusion, this study elucidated that CRNDE was increased in HCC and promoted migration, invasiveness and EMT progression of HCC cells via CRNDE/miR‐217/*MAPK1* axis. Specifically, CRNDE could promote HCC process as a molecular sponge of miR‐217, which targeting MAPK1 pathway. We preliminarily clarified the relationship between CRNDE and miR‐217. Promising therapeutic strategies against HCC might be established by targeting CENDE or repairing the balance between miR‐217 and *MAPK1*.
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